Arbor Biotechnologies secured $73.9 million in Series C funding, led by ARCH Venture Partners and TCGX, to advance its...

HUTCHMED and Innovent Biologics announced positive top-line results from the FRUSICA-2 Phase II/III trial. The trial investigated fruquintinib combined...

Ocugen, a biotechnology company, announced positive safety data from the first cohort of its Phase 1 clinical trial for...

Clearmind Medicine Inc. has initiated a Phase I/IIa clinical trial for CMND-100, a novel psychedelic-derived treatment for Alcohol Use...

Angitia Biopharmaceuticals announced positive Phase 1/2 trial data for AGA111, a recombinant human bone morphogenetic protein 6 (rhBMP6) designed...

Prime Medicine announced a preclinical program for alpha-1 antitrypsin deficiency (AATD), using its prime editing technology delivered via a...

Bio-Path Holdings announced positive pre-clinical results for BP1001-A, a potential obesity treatment. The drug candidate successfully reversed fatty acid-induced...

The 2025 SCOPE Summit brought together industry leaders to explore patient-centric approaches in clinical trials, addressing the critical issue...

Capricor Therapeutics announced positive three-year data from its open-label extension of the HOPE-2 clinical trial for deramiocel, a cell-based...

Cellphire Therapeutics has received FDA Fast Track Designation for CLPH-511, a frozen activated platelet injectable suspension designed to treat...